H
Hatem A. Azim
Researcher at American University of Beirut
Publications - 156
Citations - 8237
Hatem A. Azim is an academic researcher from American University of Beirut. The author has contributed to research in topics: Breast cancer & Pregnancy. The author has an hindex of 42, co-authored 150 publications receiving 6888 citations. Previous affiliations of Hatem A. Azim include Cairo University & Université libre de Bruxelles.
Papers
More filters
Journal ArticleDOI
Cancer and fertility preservation: international recommendations from an expert meeting
Matteo Lambertini,Lucia Del Mastro,Maria Carolina Pescio,Claus Yding Andersen,Hatem A. Azim,Fedro A. Peccatori,Mauro Costa,Alberto Revelli,Francesca Salvagno,Alessandra Gennari,Filippo Ubaldi,Giovanni Battista La Sala,Cristofaro De Stefano,Hamish Wallace,Ann H. Partridge,Paola Anserini +15 more
TL;DR: Although there is a great interest in this field, due to the lack of large prospective cohort studies and randomized trials on these topics, the level of evidence is not higher than 3 for most of the recommendations highlighting the need of further research efforts in many areas of this field.
Journal ArticleDOI
Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Fedro A. Peccatori,Hatem A. Azim,Roberto Orecchia,Harald J. Hoekstra,Nicholas Pavlidis,V. Kesic,George Pentheroudakis +6 more
TL;DR: The aim of this work is to provide a systematic review and meta-analysis of the literature on canine coronavirus infection and its role in infertility and procreation that has been reported on in previous studies and is concerned with the well-being of newborns.
Journal ArticleDOI
Dissecting the Heterogeneity of Triple-Negative Breast Cancer
Otto Metzger-Filho,Andrew Tutt,Evandro de Azambuja,Kamal S Saini,Giuseppe Viale,Sherene Loi,Ian Bradbury,Judith M Bliss,Hatem A. Azim,Paul Ellis,Angelo Di Leo,José Baselga,Christos Sotiriou,Martine Piccart-Gebhart +13 more
TL;DR: The biology of TNBC at the pathologic and the molecular levels is discussed and the role of systemic therapies and the results of the first phase III clinical trial evaluating the addition of iniparib are elaborate.
Journal ArticleDOI
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response
Evandro de Azambuja,Andrew P. Holmes,Martine Piccart-Gebhart,Eileen Holmes,Serena Di Cosimo,Ramona F. Swaby,Michael Untch,Christian Jackisch,István Láng,Ian E. Smith,Frances M. Boyle,Binghe Xu,Carlos H. Barrios,Edith A. Perez,Hatem A. Azim,Sung Bae Kim,Sherko Kuemmel,Chiun-Sheng Huang,Peter Vuylsteke,Ruey Kuen Hsieh,Vera Gorbunova,Alexandru Eniu,Lydia Dreosti,Natalia Tavartkiladze,Richard D. Gelber,Holger Eidtmann,José Baselga +26 more
TL;DR: The NeoALTTO trial showed that 3-year event-free survival was significantly improved for women who achieved pathological complete response compared with those who did not, and the association between pathological complete responded and overall survival was assessed.
Journal ArticleDOI
An update on PARP inhibitors—moving to the adjuvant setting
TL;DR: The evolution of PARP inhibitors from bench to bedside is described, and the up-to-date description of the key published or otherwise reported clinical trials of these agents are provided.